CEL-SCI CORP
CVMNYSE AMERICANTrading Snapshot
- Day Range
- $1.78 – $1.80
- 52-Week Range
- $0.89 – $10.83
- Volume
- $2.61B
- Avg Volume
- $2.88B
- Shares Outstanding
- 17.5M
- Next Earnings
- Nov 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $568,706
- Last Q Revenue
- $155,245
- P/E Ratio
- —
- P/S Ratio
- 52.6x
- EPS (TTM)
- $-2.68
- Dividend Yield
- —
- Dilution (1yr)
- +268.1%
Why Investors Own CVM
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CEL-SCI CORP
CVM
StockOtter · stockotter.spaceAbout CEL-SCI CORP
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.
CEL-SCI Reports Fiscal Third Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.